Protocol number: cv-9104-004. study name: a randomized double-blind placebo-controlled phase i/ii trial of rnactive®-derived cancer vaccine (cv9104) in asymptomatic or minimally symptomatic patients with metastatic castrate-resistant prostrate cancer

Finantzatzailea: Abf Pharmaceutical Services Gmbh

Iraupena 2013(e)ko otsaila-(a)k 20-(e)tik 2014(e)ko ekaina-(a)k 30-(e)ra izan da (16 months) Amaitu

Europar-arlokoak.